Proton pump inhibitors (PPIs) — a widely prescribed group of medications that combat heartburn, GERD (gastroesophageal reflux disease), and ulcers — are the most widely prescribed class of drugs worldwide, with annual global sales…
InflaRx shares were destroyed on Wednesday after the firm announced results from its midstage trial in patients suffering from moderate to severe hidradenitis suppurativa.
Prices for dozens of popular prescription drugs increased, sometimes doubling in cost, over the five-year period from 2012 to 2017, according to a new study published on the American Medical Association’s JAMA Network Open…
ReWalk Robotics shares absolutely exploded on Wednesday on news that the FDA has cleared the firm's ReStore soft exo-suit system for sale to rehabilitation centers across the United States.
Contents of some herbal supplements sold across the country in vitamin and nutrition stores may pose a significant danger to some people. The FDA is warning that pregnant women are particularly at risk.
A researcher at the University of Arizona, working in collaboration with other scientists across the country and in Canada, has been developing new technology that might mean diabetics will no longer need multiple daily…
Amgen is the largest of all biotechs now, and it is being deemed an "ASCO winner" for cancer and oncology news. At least, that is the view of Credit Suisse.
Here is why Genocea Biosciences is one of the big winners from the annual meeting of the American Society of Clinical Oncology (ASCO).
Turning Point Therapeutics shares dipped on Friday after the firm posted interim data for its midstage study in ROS1-positive non-small cell lung cancer patients.
As the cost of U.S. health care services and medications continue to grow at an alarming pace, Americans are now more likely to cite health care costs at their top financial problem, according to…
Cara Therapeutics recently announced data from its late-stage trial in patients with chronic kidney disease. While there was a very positive reaction among investors, one analyst believes that this stock could soar even higher.
Most people probably prefer to avoid going to the hospital if possible. It’s a choice of last resort, when we’re too sick for the doctor’s office, or need sophisticated tests or serious surgery. If…
Inovio Pharmaceuticals shares dipped on Wednesday after it was announced that the firm’s partnership with AstraZeneca would be scaled back.
AnaptysBio has been called on to have as much as 82% upside in a Credit Suisse research report. There is a scenario in which the analyst even sees as much as 200% upside.
Cara shares jumped on Wednesday after the firm announced topline data from its late-stage trial in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus.
